ClinicalTrials.gg

Program

ritlecitinib

Also written as “PF-06651600”, “Ritlecitinib” and “Ritlecitinib 50 mg”.

Its studies are mostly in Alopecia Areata · Vitiligo · Arthritis, Rheumatoid · Hidradenitis Suppurativa · Chronic Urticaria, led by Pfizer.

Furthest: phase 3, since Nov 5, 201842 company-led studies, 8 open or runningNext primary completion: Dec 2, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer428 open or runningphase 3since Nov 5, 2018Feb 12, 2016Dec 2, 2026phase 3 · NCT07029711

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 25 studies since Feb 12, 2016.

  1. Nov 2, 2020Phase 1 study in Healthy ParticipantsNCT04634565 · 9 enrolled · China
  2. Sep 2, 2021Phase 1 study in Healthy ParticipantsNCT05040295 · 12 enrolled · United States
  3. Oct 14, 20212 phase 1 studiesNCT05097716, NCT05128058
  4. Oct 6, 2022Phase 3 study in Stable Nonsegmental VitiligoNCT05583526 · 607 enrolled · United States, Australia, Bulgaria and more
  5. Dec 6, 2022Phase 1 study in Alopecia AreataNCT05650333 · 15 enrolled · United States
  6. May 1, 2023Phase 1 study in Healthy VolunteersNCT05852340 · 12 enrolled · Belgium
  7. Oct 2, 2023Phase 3 study in Stable Nonsegmental VitiligoNCT06072183 · 1,571 enrolled · United States, Australia, Belgium and more
  8. Nov 30, 2023Phase 3 study in VitiligoNCT06163326 · 394 enrolled · United States, Australia, Bulgaria and more
  9. Dec 7, 2023Phase 1 study in Healthy VolunteersNCT06172348 · 12 enrolled · Belgium
  10. Apr 11, 2024Phase 1 study in Healthy VolunteersNCT06369454 · 12 enrolled · United States
  11. Mar 7, 2025Phase 3 study in Alopecia AreataNCT06873945 · 674 planned · United States, Canada, China and more
  12. Jun 11, 20252 phase 3 studies in Alopecia AreataNCT07029828, NCT07029711
  13. Oct 20, 20252 phase 2 studiesNCT07219615, NCT07228390
  14. Jul 24, 2026Phase 3 study in Alopecia AreataNCT07733765 · 336 planned · United States, Canada, China and more

Ahead

  1. Dec 2, 2026Primary completion: phase 3 study in Alopecia AreataNCT07029711
  2. Dec 8, 2026Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07228390
  3. Dec 25, 2026Primary completion: phase 2 study in Chronic UrticariaNCT07219615
  4. Mar 31, 2027Primary completion: phase 3 study in VitiligoNCT06163326

TargetBeta

“An orally available small-molecule inhibitor of tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) ”NCIt, by rule
“Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor; Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor”ChEMBL 37, by rule

Studies

All 42 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07733765Alopecia Areata · United States, Canada, China and more3RecruitingApr 26, 2028336
NCT07228390Hidradenitis Suppurativa · United States, Canada, Germany and more2Active, not recruitingDec 8, 2026128
NCT07219615Chronic Urticaria · United States, Bulgaria, Canada and more2RecruitingDec 25, 2026200
NCT07029828Alopecia Areata · United States, China, Czechia and more3RecruitingJun 26, 2030140
NCT07029711Alopecia Areata · United States, China, Czechia and more3Active, not recruitingDec 2, 2026208
NCT06873945Alopecia Areata · United States, Canada, China and more3RecruitingMar 19, 2028674
NCT06369454Healthy Volunteers · United States1CompletedJul 31, 202412
NCT06172348Healthy Volunteers · Belgium1CompletedMar 28, 202412
NCT06163326Vitiligo · United States, Australia, Bulgaria and more3Active, not recruitingMar 31, 2027394
NCT06072183Stable Nonsegmental Vitiligo · United States, Australia, Belgium and more3Active, not recruitingJul 30, 20271,571
NCT05852340Healthy Volunteers · Belgium1CompletedJun 15, 202312
NCT05650333Alopecia Areata · United States1CompletedAug 11, 202315
NCT05583526Stable Nonsegmental Vitiligo · United States, Australia, Bulgaria and more3CompletedFeb 5, 2026607
NCT05128058Healthy · United States1CompletedJan 14, 202216
NCT05097716Healthy Volunteers · United States1CompletedJan 10, 202212
NCT05040295Healthy Participants · United States1CompletedNov 19, 202112
NCT04634565Healthy Participants · China1CompletedNov 19, 20209
NCT04517864Alopecia Areata · United States, Australia, Canada and more2TerminatedJan 4, 202271
NCT04413617Arthritis, Rheumatoid · Bulgaria, Canada, Chile and more2CompletedFeb 7, 2022460
NCT04390776Healthy Participants · United States1CompletedJul 19, 2021164
NCT04355845Healthy Volunteers · United States1CompletedAug 10, 202010
NCT04266509Healthy Volunteers · Belgium1CompletedSep 10, 202012
NCT04092595Healthy Volunteers · Belgium1CompletedJan 15, 202012
NCT04037865Renal Insufficiency · United States1TerminatedMar 31, 20208
NCT04018274Healthy · United States1CompletedOct 16, 201929
NCT04016077Hepatic Impairment · United States1CompletedMar 5, 202018
NCT04006457Alopecia Areata · United States, Argentina, Australia and more3CompletedJun 25, 20241,057
NCT04004663Healthy Volunteers · Belgium1CompletedOct 11, 201912
NCT03929510Healthy Volunteers · Netherlands1CompletedJul 5, 20196
NCT03916393Healthy Participants · Belgium1CompletedMay 10, 201910
NCT03827668Healthy · United States1CompletedApr 29, 201915
NCT03821493Healthy Participants · Belgium1CompletedApr 6, 201912
NCT03762928Healthy Subjects · United States1CompletedJan 27, 201912
NCT03732807Alopecia Areata · United States, Argentina, Australia and more3CompletedDec 31, 2020718
NCT03715829Active Non-segmental Vitiligo · United States, Australia, Belgium and more2CompletedFeb 5, 2021366
NCT03608241Healthy Females · United States1CompletedNov 23, 201812
NCT03395184Crohn Disease · United States, Australia, Austria and more2CompletedOct 19, 2023244
NCT03232905Healthy · Belgium1CompletedOct 27, 20176
NCT02974868Alopecia Areata · United States, Australia, Canada2CompletedMay 15, 2019142
NCT02969044Arthritis, Rheumatoid · United States, Bulgaria, Czechia and more2CompletedDec 12, 201770
NCT02958865Colitis, Ulcerative · United States, Austria, Bulgaria and more2CompletedMay 10, 2021319
NCT02684760Inflammatory Bowel Diseases · Belgium1CompletedMay 201614

How it is read

Names in the registry

  • “PF-06651600”, 25 entries
  • “Ritlecitinib”, 9 entries
  • “Ritlecitinib 50 mg”, 4 entries
  • “Ritlecitinib 100 mg”, 4 entries
  • “ritlecitinib”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.